Skip to content

Clinical trials

Observational Cardiomyopathies trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Cardiomyopathies Phase: Observational Country / region: United States Clear all

97 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20012
20023
20032
20043
20052
20067
20075
20084
20092
20106
20122
20132
20146
20154
20163
20173
20185
20193
20202
20213
20226
20235
20246
20254
20266

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed48
Recruiting24
Active, not recruiting7
Unknown status7
Enrolling by invitation5
Terminated3
Not yet recruiting2
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Mayo Clinic5
National Heart, Lung, and Blood Institute (NHLBI)5
Emory University4
Johns Hopkins University3
Lexeo Therapeutics3
Medtronic Cardiac Rhythm and Heart Failure3
University of Pittsburgh3
Vanderbilt University Medical Center3
Abbott Medical Devices2
Alnylam Pharmaceuticals2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Cardiomyopathies97
Heart Failure35
Arrhythmias, Cardiac10
Death, Sudden, Cardiac10
Heart Diseases8
Amyloidosis7
Cardiovascular Diseases7
Arrhythmogenic Right Ventricular Dysplasia6
Cardiomyopathy, Hypertrophic5
Heart Defects, Congenital5

Trials

Showing 1 to 25 of 97. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.